Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
28 06 2022
Historique:
received: 11 03 2022
accepted: 20 06 2022
entrez: 28 6 2022
pubmed: 29 6 2022
medline: 1 7 2022
Statut: epublish

Résumé

Recent data indicate that MIR142 is the most frequently mutated miRNA gene and one of the most frequently mutated noncoding elements in all cancers, with mutations occurring predominantly in blood cancers, especially diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Functional analyses show that the MIR142 alterations have profound consequences for lympho- and myelopoiesis. Furthermore, one of the targets downregulated by miR-142-5p is CD274, which encodes PD-L1 that is elevated in many cancer types, including myeloproliferative neoplasms (MPNs). To extend knowledge about the occurrence of MIR142 mutations, we sequenced the gene in a large panel of MPNs [~ 700 samples, including polycythemia vera, essential thrombocythemia, primary myelofibrosis (PMF), and chronic myeloid leukemia], neoplasm types in which such mutations have never been tested, and in panels of acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). We identified 3 mutations (one in a PMF sample and two others in one CLL sample), indicating that MIR142 mutations are rare in MPNs. In summary, mutations in MIR142 are rare in MPNs; however, in specific subtypes, such as PMF, their frequency may be comparable to that observed in CLL or AML.

Identifiants

pubmed: 35764886
doi: 10.1038/s41598-022-15162-1
pii: 10.1038/s41598-022-15162-1
pmc: PMC9240003
doi:

Substances chimiques

MIRN142 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10924

Informations de copyright

© 2022. The Author(s).

Références

Med Oncol. 2013 Jun;30(2):527
pubmed: 23532815
Leukemia. 2003 Dec;17(12):2474-86
pubmed: 14562124
Nat Rev Cancer. 2021 Aug;21(8):500-509
pubmed: 34230647
NPJ Genom Med. 2018 Jan 11;3:1
pubmed: 29354286
Nat Commun. 2015 Oct 05;6:8523
pubmed: 26436920
Haematologica. 2015 Apr;100(4):e122-4
pubmed: 25552704
Trends Genet. 2019 Mar;35(3):215-222
pubmed: 30638669
PLoS One. 2016 Aug 16;11(8):e0160489
pubmed: 27529619
Haematologica. 2012 Mar;97(3):388-92
pubmed: 22058207
Nat Commun. 2013;4:2185
pubmed: 23887589
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Hum Cell. 2020 Oct;33(4):1099-1111
pubmed: 32430672
Br J Haematol. 2010 Apr;149(2):250-7
pubmed: 20151976
Med Sci Monit. 2016 Oct 31;22:4114-4120
pubmed: 27796281
Nucleic Acids Res. 2012 Aug;40(14):e112
pubmed: 22539264
EBioMedicine. 2020 Nov;61:103051
pubmed: 33038763
Cancer Res. 2022 Mar 1;82(5):749-763
pubmed: 34911786
Biomed Pharmacother. 2018 Jan;97:1479-1485
pubmed: 29793310
Sci Rep. 2020 Nov 10;10(1):19390
pubmed: 33173219
PLoS One. 2012;7(9):e45760
pubmed: 23029227
EBioMedicine. 2020 Nov;61:103084
pubmed: 33096481
Leukemia. 2018 Jul;32(7):1631-1642
pubmed: 29654267
Biochem Biophys Res Commun. 2017 Jun 24;488(2):425-431
pubmed: 28511795
Cancers (Basel). 2019 Jun 08;11(6):
pubmed: 31181801
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Nucleic Acids Res. 2003 Jul 1;31(13):3406-15
pubmed: 12824337
Oncol Rep. 2018 Jul;40(1):272-282
pubmed: 29767245
Blood. 2015 Jun 11;125(24):3720-30
pubmed: 25931583
Leukemia. 2012 Mar;26(3):475-80
pubmed: 21912393
Immunity. 2019 Sep 17;51(3):479-490.e6
pubmed: 31402259
Sci Transl Med. 2018 Feb 21;10(429):
pubmed: 29467301
STAR Protoc. 2021 Dec 15;3(1):101023
pubmed: 34977675
Blood. 2011 Jun 9;117(23):6172-83
pubmed: 21474672
EMBO J. 2019 Jul 1;38(13):e101153
pubmed: 31268608
Cancer Med. 2012 Oct;1(2):141-55
pubmed: 23342264
PLoS One. 2014 Dec 26;9(12):e115693
pubmed: 25541999
Cancer Res. 2018 Jul 1;78(13):3510-3521
pubmed: 29724719
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Br J Haematol. 2009 Jun;145(6):788-800
pubmed: 19388938
J Mol Med (Berl). 2013 Aug;91(8):989-1000
pubmed: 23619912
Leukemia. 2014 Jul;28(7):1472-7
pubmed: 24402162
Leukemia. 2014 Feb;28(2):431-3
pubmed: 24097336
Br J Haematol. 2007 Mar;136(5):745-51
pubmed: 17313377

Auteurs

Paulina Galka-Marciniak (P)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.

Zuzanna Kanduła (Z)

Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.

Adrian Tire (A)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.

Wladyslaw Wegorek (W)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.

Kinga Gwozdz-Bak (K)

Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.

Luiza Handschuh (L)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Institute of Computing Science, Poznan University of Technology, Poznan, Poland.

Maciej Giefing (M)

Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.

Krzysztof Lewandowski (K)

Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.

Piotr Kozlowski (P)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland. kozlowp@ibch.poznan.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH